Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950638 · ClinicalTrials.gov registry record · Phase 1
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
A Phase 1 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00950638: Completed Phase 1 study, sponsored by Ophthotech Corporation.
NCT00950638 is a Phase 1 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00950638, a Phase 1 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
Interventions
- DRUG Avacincaptad Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-07-16 |
| Est. Completion | 2011-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00950638
The ClinicalTrials.gov registry entry for NCT00950638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avacincaptad Pegol is the first listed.
NCT00950638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00950638 about?
NCT00950638 is a clinical study titled "A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration". The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
What is the current status of trial NCT00950638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2009-07-16. Estimated completion is 2011-03-24.
What interventions are being tested in trial NCT00950638?
The interventions under investigation include: Avacincaptad Pegol (DRUG).
Who is sponsoring clinical trial NCT00950638?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.